Search the Newsreel

HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition

Harmony Biosciences (HRMY) announced strong preliminary Q2 2026 net product revenues of $261 million for its drug Wakix, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced the departure of CFO Glenn Reicin, with …

Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion

Harmony Biosciences has reaffirmed its net revenue guidance for WAKIX in 2026, projecting between $1 billion and $1.04 billion. This outlook is supported by strong preliminary second-quarter WAKIX net revenue of approximately $261 million, marking a 30% year-over-year increase and a 21% rise from …

Matrimony.com profit declines 24.5% to ₹34.17 crore in FY26

Harmony Gold Mining Co. Ltd (HMY) Q4 2025 Earnings Report - Results, Call & Slides

Harmony Gold Mining (HMY) reported its Q4 2025 earnings, meeting EPS expectations at $0.57 while beating revenue forecasts with $2.17 billion, a 31.74% year-over-year increase. The company's actual revenue surpassed the expected $2.03 billion by $138.43 million. The earnings call took place on Thursday, …

United States Antimony Stock Dips as Gold, Silver and Dollar Rise

United States Antimony (UAMY) shares fell by 11.99% as gold, silver, and other precious metals declined. This drop is attributed to escalating Middle East tensions, particularly between US and Iranian forces, which have led to surging oil prices, rising Treasury yields, and a stronger …

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences announced record preliminary, unaudited net product revenue of approximately $261 million for WAKIX® in Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. The company also announced the departure of …

Harmony Biosciences reports record Q2 WAKIX sales of $261M

Harmony Biosciences Holdings, Inc. announced record preliminary, unaudited second-quarter 2026 net product revenue of $261 million for WAKIX, representing a 30% year-over-year increase. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, driven by strong demand and …

Harmony Biosciences Announces CFO Transition as Glenn Reicin Steps Down

Harmony Biosciences announced that CFO Glenn Reicin has stepped down, effective July 16, 2026, to pursue other opportunities. Stephen Mollichella, SVP and controller, has been appointed interim principal financial officer. The company also reported record preliminary second-quarter revenue of approximately $261 million for WAKIX® …

GUIDANCE: (HRMY) Harmony Biosciences Expects Q2 Wakix Net Product Revenue About $261M

Harmony Biosciences (HRMY) announced it expects its second-quarter Wakix net product revenue to be approximately $261 million. This projection indicates continued strong performance for their primary product. The financial guidance provides a positive outlook for the company's Q2 results.

Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement

Harmony Biosciences reported preliminary second-quarter net product revenue for WAKIX of approximately $261 million, a new record, and reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced that CFO Glenn Reicin stepped down, with Stephen Mollichella appointed …

Harmony Bio stock drops after CFO exit (HRMY:NASDAQ)

Harmony Biosciences (HRMY) stock declined following the resignation of its Chief Financial Officer, Glenn Reicin, who left to pursue other career opportunities. Stephen Mollichella, the SVP and Controller, has been appointed as the Interim Principal Financial Officer to oversee financial operations for the rare …

Harmony Biosciences (HRMY) AGM 2026 Summary

Harmony Biosciences held its 2026 Annual General Meeting (AGM) on May 18, 2026, where four Class 3 directors were nominated for election, and shareholders were asked to vote on the election of directors, ratification of Deloitte & Touche LLP as independent auditor, and a …

Harmony Biosciences (HRMY) Q4 2025 earnings summary

Harmony Biosciences reported strong Q4 2025 results with net product revenue of $243.8M, a 21% year-over-year increase, and full-year revenue of $868.5M. The company provided 2026 WAKIX net revenue guidance of $1B–$1.04B, anticipating blockbuster status, and is advancing a late-stage pipeline with five Phase …

Jack-in-the-Stox: U.S. Antimony and the Return of Industrial Reality

This article discusses the rising strategic importance of antimony, moving from an obscure metal to a critical material due to Chinese export restrictions. Author Jack Lifton emphasizes that while many companies are exploring antimony mining, U.S. Antimony stands out because it already possesses established …

Harmony Gold Mining Co. Ltd. Stock 12‑Month Price Target Raised to ZAC 39291.17, Implies 55% Upside

Harmony Gold Mining Co. Ltd.'s average 12-month price target has been increased to ZAC 39291.17 from ZAC 38577.56, based on estimates from 9 analysts. This updated target suggests a potential upside of approximately 55% from the July 14 closing price. The consensus rating for …

US Antimony contracts AI firm for Los Juarez silver mine project

United States Antimony Corporation (NYSE:UAMY) has hired an artificial intelligence firm to analyze historical geological data for its inactive Los Juarez Silver Mine in Mexico, aiming to significantly reduce data processing timelines. This strategic move is intended to evaluate the mine's potential given current …

United States Antimony Announces Utilization of AI Technology into Certain Mining Projects

United States Antimony Corporation (USAC) has contracted an AI firm to incorporate artificial intelligence technology into its mining projects, starting with the Los Juarez Silver Mine in Mexico. The goal is to reduce risk, expedite production, and leverage historical geological data to enhance probabilistic …

US Antimony Reprocesses Years of Mine Data in Weeks With AI

United States Antimony (NYSE: UAMY) has contracted an AI firm specializing in hard rock mining to reprocess historical data for its Los Juarez Silver Mine project in Mexico. This initiative aims to reduce risk, accelerate production decisions, and "high grade" the asset's potential by …

MONY Forecast — Price Target — Prediction for 2027

Tech Query: Mahindra & Mahindra (M&M), Indian Overseas Bank (IOB), Matrimony.com, EID Parry India - What is the outlook? Where are these stocks headed?

Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?

Harmony Gold Share Price 2026: Technical Analysis, Valuation Metrics, and Investment Outlook

Zacks Industry Outlook Highlights Franco-Nevada, Harmony Gold, Novagold Resources, DRDGOLD and Idaho Strategic Resources

Matrimony.com Q4 PAT Rises 18.9%; Profit To Double

Harmony Gold Mining Co Ltd (HMY) Shares Fall 9.6% -- What GF Sco

Matrimony.com Consolidated March 2026 Net Sales at Rs 121.79 crore, up 12.44% Y-o-Y

Matrimony.com posts Rs 117 Cr revenue and Rs 10 Cr profit in Q4 FY26

Matrimony.com consolidated net profit rises 18.70% in the March 2026 quarter

Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality

Earnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their Forecasts

Should Harmony Biosciences’ Softer Q1 2026 Earnings and Upbeat Forecasts Require Action From HRMY Investors?

MoneySuperMarket parent MONY reiterates expectations as revenue rises

Harmony Gold Mining Company Limited (JSE:HAR) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Should You Be Adding Harmony Gold Mining (JSE:HAR) To Your Watchlist Today?

If EPS Growth Is Important To You, Harmony Gold Mining (JSE:HAR) Presents An Opportunity

South Africa’s largest gold producer Harmony posts 13% profit jump, pays $208 million dividend to shareholders